

## **Supplemental Materials for**

### **BTK Inhibitors for the treatment of relapsed or refractory mantle cell lymphoma**

Carolyn Owen MD, Neil L. Berinstein MD, Anna Christofides MSc RD, Laurie H. Sehn MD

#### **Listing of Supplemental Material(s):**

Supplemental Appendix 1: Key studies of BTK inhibitors in other hematological malignancies

**Supplemental Appendix 1: Key studies of BTK inhibitors in other hematological malignancies**

Study	Phase	Disease	Treatment	ORR (%)	PFS	OS
<b>Completed Studies (Phase 2/3)</b>						
Byrd et al. 2013	Ib/II	RR CLL	Ibrutinib	71	26-month: 75%	26-month: 83%
Byrd et al. 2014	III	RR CLL	Ibrutinib	63	6-month: 88%	12-month: 90%
Burger et al. 2014	II	RR CLL	Ibrutinib/Rituximab	95	18-month: 78%	18-month: 84%
Chanan-Khan et al. 2016	III	RR CLL	Ibrutinib/Bendamustine/ Rituximab	83	18-month: 79%	NR
Byrd et al. 2016*	I/II	RR CLL	Acalabrutinib	95	2 events	1 event
Coutre et al. 2017	Ib/II	1L CLL	Ibrutinib	85	30-month: 96%	30-month: 96%
Burger et al. 2015	III	1L CLL	Ibrutinib	86	30-month: 90%	24-month: 98%
Treon et al. 2015	II	RR WM	Ibrutinib	91	24-month: 69%	24-month: 95%
Wilson et al. 2015 <sup>†</sup>	II	ABC- DLBCL	Ibrutinib	37	2 months	10 months
Noy et al. 2017 <sup>‡</sup>	II	MZL	Ibrutinib	51	14 months	18-month: 81%
<b>Ongoing Phase III studies</b>						
NCT02301156	III	RR High- Risk CLL	Ibrutinib + Ublituximab vs Ibrutinib			
NCT02477696	III	RR High- Risk CLL	Acalabrutinib vs Ibrutinib			
NCT02970318	III	RR CLL	Acalabrutinib vs Idelalisib + Rituximab or Bendamustine + Rituximab			
NCT03462719	III	1L CLL/SLL	Ibrutinib + Venetoclax vs Chlorambucil + Obinutuzumab			
NCT02264574	III	1L CLL/SLL	Ibrutinib + Obinutuzumab vs Chlorambucil + Obinutuzumab			
NCT01886872	III	1L CLL	Ibrutinib + Rituximab vs Ibrutinib vs Rituximab + Bendamustine			
NCT02950051	III	1L CLL without del(17p)	Ibrutinib + Obinutuzumab + Venetoclax vs Standard chemo vs Rituximab + Venetoclax vs Obinutuzumab + Venetoclax			
NCT01886872	III	1L CLL Older Pts	Ibrutinib + Rituximab vs BR vs Ibrutinib			
NCT02048813	III	1L CLL/SLL	Ibrutinib + Rituximab vs FCR			
NCT02475681	III	1L CLL/SLL	Acalabrutinib + Obinutuzumab vs Obinutuzumab + Chlorambucil vs Acalabrutinib			
NCT03336333	III	1L CLL	Zanubrutinib vs BR			
NCT03053440	III	WM	Zanubrutinib vs Ibrutinib			
NCT02972840	III	1L MCL	Acalabrutinib vs Bendamustine + Rituximab			
NCT01974440	III	RR iNHL	Ibrutinib + BR or R-CHOP			

*BR, bendamustine, rituximab; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FCR, fludarabine, cyclophosphamide, rituximab; iNHL, indolent non-Hodgkin lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; NR, not reached; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; R-CHOP, rituximab, cyclophosphamide, vincristine, doxorubicin; prednisone; RR, relapsed or refractory; SLL, small lymphocytic lymphoma; WM, Waldenström's Macroglobulinemia*

*\*Median follow-up of 14.3 months; †Median follow-up of 10.12 months; ‡Median follow-up of 19.4 months*